Drug Type Antibody drug conjugate (ADC) |
Synonyms extracellular drug conjugate-3, extracellular drug conjugate-3 (Centrose), EDC-3 |
Target |
Action inhibitors, modulators |
Mechanism Na/K-ATPase inhibitors(Sodium/potassium-transporting ATPase inhibitors), SLC3A2 modulators(solute carrier family 3 member 2 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingDiscovery |
First Approval Date- |
Regulation- |
Molecular FormulaC24H32O4 |
InChIKeyOVUOVMIMOCJILI-KFZANIOBSA-N |
CAS Registry465-22-5 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus | Discovery | United States | - | |
| Inflammation | Discovery | United States | - | |
| Neoplasms | Discovery | United States | - |






